Scientists Reveal How Cell Division Hubs Are Policed by Protein Destruction

Human cells rely on a precise molecular pruning system to keep their major microtubule-organizing centers at the right size, and researchers have finally uncovered the exact trigger that controls this process. Centrosomes act as the command hubs for cellular division, but when the scaffolding protein Cep192 builds up unchecked, it causes severe mitotic arrest and cell death. A team of cell biologists set out to decode how the enzyme TRIM37 targets Cep192 for destruction, discovering a dual-part signal that governs protein stability and guards against chromosomal instability.

The study, published in The Journal of Cell Biology, demonstrates that the ubiquitin ligase TRIM37 directly recognizes a specific sequence on the C terminus of the massive 307 kilodalton Cep192 protein. Lead author Weronika E. Stachera and colleagues established an in vitro ubiquitination assay using purified components from baculovirus-infected insect cells to prove direct interaction. Mass spectrometry analysis revealed that TRIM37 attaches molecular tags to a cluster of seven specific lysine residues located near the very end of Cep192, effectively marking the protein for proteasome-mediated degradation.

What is the bipartite degron that triggers destruction?

To pinpoint how the cellular machinery recognizes its target, the researchers mapped the docking interface on Cep192. They found that a composite region consisting of an intrinsically disordered region paired with a structured beta-barrel domain known as ASH8, collectively called IDR plus ASH8, is strictly required for stable binding. When the team mutated this recognition domain or altered the seven target lysines into arginines, Cep192 accumulated to abnormally high levels inside human colorectal cells, preventing normal protein turnover.

Further experiments showed that this specialized recognition module acts as a universal disposal ticket. When the authors fused the IDR plus ASH8 domain onto unrelated proteins such as the microtubule end-binding protein EB1 or monomeric green fluorescent protein, those proteins were rapidly degraded by TRIM37. This discovery confirms that the domain functions as a bona fide degron, capable of converting non-targeted proteins into substrates without requiring centrosome localization or higher-order protein clumping.

How do structural interactions drive high-affinity binding?

Biochemical assays and cross-linking mass spectrometry shed light on the physical architecture of the TRIM37 and Cep192 complex. The binding occurs with a strong mid-nanomolar affinity, showing an apparent dissociation constant of 75 nanomolar. Cross-linking analysis indicated that two separate coiled-coil domains on TRIM37 engage the compact beta-barrel structure of ASH8 and its preceding linker. This high-affinity interaction contrasts sharply with how TRIM37 handles other targets like Centrobin, which relies on low-affinity binding through its MATH domain to destroy large protein condensates.

When the degradation-resistant Cep192 mutants were overexpressed in human cells, the consequences were severe. Cell proliferation dropped by roughly 50 percent for the seven-lysine mutant and by about 75 percent for the domain deletion mutant. Live-cell imaging revealed that affected cells experienced prolonged metaphase arrest lasting hours instead of the normal 40-minute window, frequently culminating in mitotic failure or cell death.

What are the broader implications for cancer and rare diseases?

The findings carry significant clinical relevance because dysregulation of TRIM37 is directly tied to human pathology. The genomic locus for TRIM37 is frequently amplified in several aggressive human malignancies, including neuroblastoma, breast cancer, liver tumors, and kidney cancer, where elevated enzyme levels promote chemoresistance. Conversely, loss-of-function mutations in the gene cause Mulibrey nanism, a rare autosomal recessive growth disorder characterized by severe prenatal and postnatal growth failure.

By mapping the exact structural rules that allow TRIM37 to recognize and degrade essential centrosome components, the research opens new avenues for understanding mitotic fidelity. Although the study utilized transgene overexpression models that require cautious interpretation, identifying this bipartite recognition motif suggests that similar mixed-architecture degrons may exist across the human proteome, waiting to be uncovered.

The research was published in The Journal of cell biology on January 4, 2027.